Personal Genome Service For Carrier Screening Emerges From 23andMe Work With FDA
This article was originally published in The Tan Sheet
Two years of conversations with FDA lead 23andMe back to the health care market with the launch of its Personal Genome Service, focused on carrier screening tests. The firm says its close engagement with FDA improved its customer communication and quality control.
You may also be interested in...
The Google-backed firm's carrier screening assay for a rare disease called Bloom syndrome is the first DTC genetic test to achieve sign off from FDA. More importantly, the marketing authority was awarded in a manner that could significantly streamline the path to market for future DTC carrier-screening assays.